company background image
IMNM

Immunome NasdaqCM:IMNM Stock Report

Last Price

US$3.21

Market Cap

US$38.9m

7D

9.9%

1Y

-81.2%

Updated

30 Jun, 2022

Data

Company Financials +
IMNM fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

IMNM Stock Overview

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease.

Immunome Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Immunome
Historical stock prices
Current Share PriceUS$3.21
52 Week HighUS$27.80
52 Week LowUS$2.09
Beta0
1 Month Change-17.48%
3 Month Change-44.56%
1 Year Change-81.23%
3 Year Changen/a
5 Year Changen/a
Change since IPO-76.13%

Recent News & Updates

Jun 30

Immunome gains 34% after preclinical data on COVID-19 antibody

Clinical-stage biotech Immunome (NASDAQ:IMNM) added ~34% on Thursday on the publication of research indicating that the company’s experimental three-antibody cocktail IMM-BCP-01 was effective against COVID-19 variants of concern including BA.1 and BA.2. IMM-BCP-01 consists of three patient-derived neutralizing antibodies, designed to target non-overlapping regions on the   SARS-CoV-2 spike protein. According to results published in the journal science, IMM-BCP-01 was found to have decreased Omicron infection in the lungs of Syrian golden hamsters. The lab results have also indicated potential antiviral effector response, including phagocytosis, antibody-mediated cellular cytotoxicity, complement pathway activation. Results indicate that “IMM-BCP-01 could be a promising means for preventing or treating infection of SARS-CoV-2 variants of concern, including Omicron BA.1 and BA.2, in susceptible individuals,” researchers wrote. Early this month, Immunome (IMNM) announced the dosing initiation of an early-stage study for IMM-BCP-01 involving recently diagnosed COVID-19 patients. The topline data from the single dose, dose escalation study is expected in 2H 2022.

Shareholder Returns

IMNMUS BiotechsUS Market
7D9.9%-0.1%-0.6%
1Y-81.2%-27.0%-21.7%

Return vs Industry: IMNM underperformed the US Biotechs industry which returned -25.8% over the past year.

Return vs Market: IMNM underperformed the US Market which returned -20.8% over the past year.

Price Volatility

Is IMNM's price volatile compared to industry and market?
IMNM volatility
IMNM Average Weekly Movement17.6%
Biotechs Industry Average Movement13.2%
Market Average Movement8.0%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.2%

Stable Share Price: IMNM is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 18% a week.

Volatility Over Time: IMNM's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200639Purnanand Sarmahttps://immunome.com

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company’s lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19.

Immunome Fundamentals Summary

How do Immunome's earnings and revenue compare to its market cap?
IMNM fundamental statistics
Market CapUS$38.93m
Earnings (TTM)-US$32.47m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IMNM income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$32.47m
Earnings-US$32.47m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.68
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did IMNM perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is IMNM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IMNM?

Other financial metrics that can be useful for relative valuation.

IMNM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does IMNM's PB Ratio compare to its peers?

IMNM PB Ratio vs Peers
The above table shows the PB ratio for IMNM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average2.8x
VIRI Virios Therapeutics
3.3x26.9%US$35.2m
CDTX Cidara Therapeutics
6.8x67.1%US$33.7m
AGLE Aeglea BioTherapeutics
0.5x-13.5%US$30.9m
ALRN Aileron Therapeutics
0.7x-14.2%US$23.6m
IMNM Immunome
1x-45.5%US$38.9m

Price-To-Book vs Peers: IMNM is good value based on its Price-To-Book Ratio (1x) compared to the peer average (2.8x).


Price to Earnings Ratio vs Industry

How does IMNM's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: IMNM is good value based on its Price-To-Book Ratio (1x) compared to the US Biotechs industry average (1.6x)


Price to Book Ratio vs Fair Ratio

What is IMNM's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IMNM PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate IMNM's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of IMNM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate IMNM's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate IMNM's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IMNM's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Immunome forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-45.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IMNM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IMNM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IMNM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IMNM's revenue (129.4% per year) is forecast to grow faster than the US market (8.3% per year).

High Growth Revenue: IMNM's revenue (129.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if IMNM's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Immunome performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-40.5%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: IMNM is currently unprofitable.

Growing Profit Margin: IMNM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IMNM is unprofitable, and losses have increased over the past 5 years at a rate of 40.5% per year.

Accelerating Growth: Unable to compare IMNM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IMNM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: IMNM has a negative Return on Equity (-85.72%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Immunome's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: IMNM's short term assets ($46.3M) exceed its short term liabilities ($9.7M).

Long Term Liabilities: IMNM's short term assets ($46.3M) exceed its long term liabilities ($147.0K).


Debt to Equity History and Analysis

Debt Level: IMNM is debt free.

Reducing Debt: IMNM had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IMNM has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IMNM has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 32.9% each year.


Discover healthy companies

Dividend

What is Immunome current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate IMNM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IMNM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IMNM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IMNM's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as IMNM has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

Purnanand Sarma (56 yo)

3yrs

Tenure

US$2,112,848

Compensation

Dr. Purnanand Duddu Sarma, Ph D., has been the President and Chief Executive Officer of Immunome, Inc. since June 24, 2019 and its Director since June 2019. Dr. Sarma serves as Director of Vaxess Technolog...


CEO Compensation Analysis

Compensation vs Market: Purnanand's total compensation ($USD2.11M) is above average for companies of similar size in the US market ($USD760.83K).

Compensation vs Earnings: Purnanand's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: IMNM's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: IMNM's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.1%.


Top Shareholders

Company Information

Immunome, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Immunome, Inc.
  • Ticker: IMNM
  • Exchange: NasdaqCM
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$38.929m
  • Shares outstanding: 12.13m
  • Website: https://immunome.com

Number of Employees


Location

  • Immunome, Inc.
  • 665 Stockton Drive
  • Suite 300
  • Exton
  • Pennsylvania
  • 19341
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/30 00:00
End of Day Share Price2022/06/30 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.